巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Evolus

    EOLS
    11.740
    0.240
    2.09%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Evolus - 延遲價格・最後更新於 26/05 4:38
    最高位
    11.790
    最低位
    11.510
    開市價
    --
    前收市價
    11.500
    成交量(千)
    3.37
    成交額(百萬)
    0.39
    買入
    11.760
    賣出
    11.790
    每手股數
    --
    市值(百萬)
    658.02
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    14.340 - 5.061
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Evolus
    證券代碼
    EOLS.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company generates product revenue from the sale of Jeuveau in the US.
    發行量
    56045240
    公司總部
    520 Newport Center Drive, Suite 1200
    公司網址
    https://www.evolus.com
    公司電郵
    IR@Evolus.com
    公司電話
    +1 949 284-4555
    暫無內容

    關於

    Evolus(EOLS.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company generates product revenue from the sale of Jeuveau in the US.
    詳細公司背景可參考: https://www.evolus.com